Israel Active

Some 8 years ago (see ) the US Navy bought several Deep TMS therapy helmets made by Israel’s Brainsway to treat service personnel with PTSD and other conditions. The US military will now provide them to soldiers and veterans for a range of brain disorders.

Doctors at Israeli NGO Save A Child’s Heart have, for the first time, implanted an innovative pacemaker into a teenage Palestinian Arab girl from Gaza, via her neck rather than groin. The pacemaker is identical to that recently implanted into Israel’s Prime Minister.

Although still in development, the ART500 blood oxygenator from Israel’s Inspira Technologies (see previously) could save millions of lives, making it unnecessary to induce coma and intubate patients who cannot breathe on their own.  Worth watching the video.

Israel’s Alpha Tau (see previously) has used its Alpha DaRT technology to treat the first Israeli patient with advanced inoperable pancreatic cancer in a clinical trial at Hadassah Medical Center in Jerusalem.

Researchers at Israel’s Technion have developed an AI system that identified 77 approved cancer nano-therapies that can chemically self-assemble in nearly 2,000 combinations to be far more effective, with less side-effects. They proved their system, combining bortezomib-cabozantinib to treat head/neck cancer.

GranaGard Nano Omega 5, made by Israel’s Granalix Biotechnologies, is now available in Israel and online. The nano-engineered high antioxidant supplement from pomegranate oil improves cognitive function in Multiple Sclerosis patients and will be tested on dementia patients.

Israel’s Limaca Medical (see previously) has received US FDA approval for its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device. The device automatically obtains biopsies, for diagnosis of pancreatic cancer and other cancers, quicker and safer than current products.

Israel’s Techsomed (see previously) has received US FDA approval for its Ablation Treatment Planning and Confirmation Software. VisAble.IO helps guide surgeons using ablation therapy (extreme heat or cold) to destroy tumors.

Israel’s Elgan Pharma (see previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal (GI) system.

Israel’s Nasus Pharma (see previously) has reported positive results from its latest clinical study of its FMXIN002 intranasal Epinephrine powder spray device. It provides a safe and effective rescue for the emergency treatment of life-threatening allergic reactions.